Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
Key result
Higher axitinib exposure and diastolic blood pressure were independently associated with longer progression-free and overall survivals and higher probability of partial response in metastatic RCC.
Why the study?
Are axitinib exposure and diastolic blood pressure associated with improved survival and response in patients with metastatic renal cell carcinoma?
Population
590 individuals pooled from 17 trials, including 383 healthy volunteers, 181 patients with metastatic renal…
Design
Other
Authors
Discussion
Loading...
Member takes
Implication
May support exposure- and BP-guided axitinib dosing in mRCC; leaves open prospective randomized validation before practice change.
Structured PICO
Are axitinib exposure and diastolic blood pressure associated with improved survival and response in patients with metastatic renal cell carcinoma?
P
Population
590 participants, comprising 383 healthy volunteers, 181 patients with metastatic RCC, and 26 with other solid tumors, pooled from 17 trials for pharmacokinetic and pharmacodynamic analysis.
E
Exposure
Axitinib (pharmacokinetic and pharmacodynamic modeling)
O
Outcome
Pharmacokinetic parameters (systemic clearance and central volume of distribution) and clinical outcomes (progression-free survival, overall survival, and probability of partial response)
Higher axitinib exposure and diastolic blood pressure correlate with improved clinical outcomes in metastatic renal cell carcinoma, supporting individualized dose titration.
Cite This Study
Rini et al. (2013) studied Metastatic Renal Cell Carcinoma (n=590). Axitinib was evaluated on Progression-free survival, overall survival, and probability of partial response. Higher axitinib exposure and diastolic blood pressure were independently associated with longer progression-free and overall survivals and higher probability of partial response in metastatic RCC.